Anbio Biotechnology Class A(NNNN)
$3.82+0.02 (+0.53%)
NNNN
Anbio Biotechnology Class A financials statements
$3.82
At close:+0.02 (+0.53%)
Anbio Biotechnology Class A (NNNN) Ratios
62 Followers
Anbio Biotechnology Class A Ratios
NNNN's free cash flow for Q4 2025 was $0.00. For the 2025 fiscal year, NNNN's free cash flow was increased by $0.00 and operating cash flow was $0.00. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 344.31 | 10.71 | 15.86 | 9.88 | 2.07 |
| Quick Ratio | 344.31 | 10.71 | 15.86 | 9.63 | 2.07 |
| Cash Ratio | 88.42 | 6.80 | 9.76 | 5.03 | 1.76 |
| Solvency Ratio | 72.90 | 1.37 | 2.28 | 7.10 | 1.07 |
| Operating Cash Flow Ratio | -76.72 | 1.20 | 0.90 | 3.15 | 1.76 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 30.16M | $ 16.80M | $ 14.76M | $ 12.53M | $ 2.54M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.00 | 1.10 | 1.07 | 1.11 | 1.94 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 1253.34 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 1274.61 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | -1.35 | -4.58 | -4.27 | -0.71 | -1.65 |
| Profitability Margins | |||||
| Gross Profit Margin | 87.24% | 71.90% | 50.07% | 53.36% | 57.40% |
| EBIT Margin | 66.70% | 28.99% | 33.58% | 42.55% | 57.26% |
| EBITDA Margin | 66.70% | 31.36% | 33.77% | 42.58% | 57.26% |
| Operating Profit Margin | 66.70% | 24.38% | 29.22% | 43.30% | 55.46% |
| Pretax Profit Margin | 74.06% | 28.99% | 33.58% | 42.52% | 57.26% |
| Net Profit Margin | 74.06% | 28.99% | 33.58% | 42.52% | 57.26% |
| Continuous Operations Profit Margin | 74.06% | 28.99% | 33.58% | 42.52% | 57.26% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 111.02% | 118.92% | 114.93% | 98.19% | 103.25% |
| Return on Assets (ROA) | 21.17% | 12.54% | 14.25% | 71.72% | 51.59% |
| Return on Equity (ROE) | 21.24% | 13.80% | 15.21% | 79.79% | 100.00% |
| Return on Capital Employed (ROCE) | 19.13% | 11.61% | 13.23% | 81.26% | 96.85% |
| Return on Invested Capital (ROIC) | 19.13% | 11.61% | 13.23% | 81.26% | 96.85% |
| Return on Tangible Assets | 21.17% | 12.54% | 14.25% | 71.72% | 51.59% |
| Earnings Yield | 0.49% | 0.97% | 0.27% | 1.21% | 0.44% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.36 | 7.69 | 3.56 | 6574.88 | 6.17 |
| Payables Turnover | 0.00 | 1.42 | 4.05 | 7.80 | 1.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 31.03 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 1952.45 | 0.00 |
| Asset Turnover | 0.29 | 0.43 | 0.42 | 1.69 | 0.90 |
| Working Capital Turnover Ratio | 0.37 | 0.52 | 0.49 | 3.13 | 0.00 |
| Cash Conversion Cycle | 154.37 | -210.47 | 12.41 | -34.98 | -306.51 |
| Days of Sales Outstanding | 154.37 | 47.48 | 102.50 | 0.06 | 59.14 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 11.76 | 0.00 |
| Days of Payables Outstanding | 0.00 | 257.95 | 90.09 | 46.80 | 365.65 |
| Operating Cycle | 154.37 | 47.48 | 102.50 | 11.82 | 59.14 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.15 | 0.05 | 0.01 | 0.03 | 0.04 |
| Free Cash Flow Per Share | -0.15 | 0.05 | 0.01 | 0.03 | 0.04 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 1542301.40 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 1542301.40 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | -0.78 | 0.25 | 0.13 | 0.19 | 0.94 |
| Free Cash Flow Yield | -0.51% | 0.85% | 0.11% | 0.54% | 0.72% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 187.94 | 103.04 | 368.39 | 82.93 | 227.54 |
| Price-to-Sales (P/S) Ratio | 152.63 | 29.81 | 123.70 | 35.26 | 130.29 |
| Price-to-Book (P/B) Ratio | 43.77 | 14.19 | 56.03 | 66.17 | 227.54 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -195.84 | 117.30 | 924.18 | 186.62 | 137.99 |
| Price-to-Operating Cash Flow Ratio | -195.84 | 117.30 | 924.18 | 186.62 | 137.99 |
| Price-to-Earnings Growth (PEG) Ratio | 1.01 | 0.40 | -4.76 | 0.48 | 0.00 |
| Enterprise Value Multiple | 227.48 | 90.49 | 362.00 | 82.11 | 225.89 |
| Enterprise Value | 1.31B | 232.26M | 820.56M | 823.15M | 572.82M |
| EV to EBITDA | 227.48 | 90.49 | 362.00 | 82.11 | 225.89 |
| EV to Sales | 151.74 | 28.38 | 122.25 | 34.96 | 129.35 |
| EV to Free Cash Flow | -194.69 | 111.64 | 913.40 | 185.03 | 136.99 |
| EV to Operating Cash Flow | -194.69 | 111.64 | 913.40 | 185.03 | 136.99 |
| Tangible Book Value Per Share | 0.69 | 0.41 | 0.10 | 0.09 | 0.03 |
| Shareholders’ Equity Per Share | 0.69 | 0.41 | 0.10 | 0.09 | 0.03 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.20 | 0.19 | 0.05 | 0.16 | 0.04 |
| Net Income Per Share | 0.15 | 0.06 | 0.02 | 0.07 | 0.03 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.11 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.02 | 0.06 | 0.02 | 0.01 | 0.00 |
| SG&A to Revenue | 0.18 | 0.42 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | -1.05 | 0.88 | 0.40 | 0.44 | 1.65 |
Currency in USD
